Gertjan J L Kaspers Selected Research

Pharmaceutical Preparations

12/2020	The role of alternative splicing in cancer: From oncogenesis to drug resistance.
11/2020	Overview of Current Drug Delivery Methods Across the Blood-Brain Barrier for the Treatment of Primary Brain Tumors.
5/2020	Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia.
3/2020	Glucocorticoid Resistant Pediatric Acute Lymphoblastic Leukemia Samples Display Altered Splicing Profile and Vulnerability to Spliceosome Modulation.
1/2020	A High-Throughput Image-Guided Stereotactic Neuronavigation and Focused Ultrasound System for Blood-Brain Barrier Opening in Rodents.
1/2019	Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.
1/2018	Multiregional Tumor Drug-Uptake Imaging by PET and Microvascular Morphology in End-Stage Diffuse Intrinsic Pontine Glioma.
12/2017	A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia.
1/2017	Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates.
4/2016	Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gertjan J L Kaspers Research Topics

Disease

61	Neoplasms (Cancer) 02/2022 - 02/2003
33	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 07/2021 - 01/2002
29	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 05/2003
23	Diffuse Intrinsic Pontine Glioma 06/2021 - 02/2013
14	Leukemia 01/2021 - 01/2002
12	Glioma (Gliomas) 06/2022 - 12/2011
9	Brain Neoplasms (Brain Tumor) 06/2022 - 02/2003
6	Glioblastoma (Glioblastoma Multiforme) 11/2020 - 06/2009
5	Hypersensitivity (Allergy) 01/2019 - 05/2013
5	Hematologic Neoplasms (Hematological Malignancy) 01/2015 - 06/2003
4	Medulloblastoma 11/2020 - 02/2003
4	Fatigue 01/2020 - 09/2011
3	Peripheral Nervous System Diseases (PNS Diseases) 01/2022 - 12/2020
3	Carcinogenesis 12/2020 - 02/2009
3	Residual Neoplasm 12/2014 - 10/2005
3	Carcinoma (Carcinomatosis) 05/2014 - 03/2003
3	Osteosarcoma (Osteogenic Sarcoma) 04/2011 - 03/2005
2	Disease Progression 06/2021 - 10/2019
2	Infections 01/2019 - 08/2015
2	Breast Neoplasms (Breast Cancer) 01/2019 - 02/2017
2	Acute Promyelocytic Leukemia 01/2018 - 09/2017
2	Retinoblastoma (Glioblastoma, Retinal) 01/2017 - 01/2016
2	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell) 01/2016 - 07/2014
2	Brain Stem Neoplasms (Brain Stem Tumor) 12/2014 - 01/2014
2	Ependymoma 07/2014 - 12/2011
2	Neoplasm Metastasis (Metastasis) 04/2011 - 01/2008
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 04/2008 - 01/2006
1	Chronic Renal Insufficiency 11/2022
1	Albuminuria 11/2022
1	Proteinuria 06/2022
1	Sleep Wake Disorders 02/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Rhabdoid Tumor (Rhabdoid Tumors) 11/2020
1	Procedural Pain 05/2020
1	Pain (Aches) 05/2020

Drug/Important Bio-Agent (IBA)

22	dipinacoline glutamateIBA 06/2021 - 02/2013
16	Pharmaceutical PreparationsIBA 12/2020 - 01/2002
10	Proteins (Proteins, Gene)FDA Link 06/2022 - 04/2008
7	Asparaginase (Elspar)FDA Link 01/2019 - 01/2005
6	Methotrexate (Mexate)FDA LinkGeneric 07/2021 - 07/2005
6	Bortezomib (Velcade)FDA Link 01/2021 - 12/2013
5	Proteasome InhibitorsIBA 01/2021 - 12/2013
5	Dexamethasone (Maxidex)FDA LinkGeneric 11/2020 - 09/2012
5	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2020 - 12/2004
5	multidrug resistance-associated protein 1IBA 01/2019 - 03/2003
5	Folic Acid (Vitamin M)FDA LinkGeneric 04/2016 - 03/2003
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2021 - 02/2008
4	Histones (Histone)IBA 01/2021 - 01/2017
4	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2021 - 12/2013
4	Phosphotransferases (Kinase)IBA 12/2020 - 10/2005
4	GlucocorticoidsIBA 03/2020 - 10/2007
4	DNA (Deoxyribonucleic Acid)IBA 12/2019 - 12/2011
3	CreatinineIBA 11/2022 - 08/2011
3	Vincristine (Oncovin)FDA LinkGeneric 01/2022 - 12/2020
3	Bevacizumab (Avastin)FDA Link 06/2021 - 01/2016
3	Gemcitabine FDA Link 01/2020 - 11/2017
3	MicroRNAs (MicroRNA)IBA 07/2016 - 06/2014
3	Hydrocortisone (Cortisol)FDA LinkGeneric 08/2015 - 09/2012
2	RNA Splicing FactorsIBA 12/2020 - 05/2015
2	RNA Precursors (Precursor, mRNA)IBA 12/2020 - 05/2015
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2019 - 12/2004
2	Thymidylate SynthaseIBA 01/2019 - 07/2005
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2019 - 06/2006
2	Transcription Factors (Transcription Factor)IBA 01/2018 - 01/2005
2	89Zr-bevacizumabIBA 01/2018 - 01/2016
2	AnthracyclinesIBA 01/2018 - 05/2017
2	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2018 - 02/2013
2	Alkylating AgentsIBA 02/2017 - 05/2012
2	folylpolyglutamate synthetaseIBA 04/2016 - 01/2016
2	Cytotoxins (Cytolysins)IBA 05/2015 - 12/2011
2	Messenger RNA (mRNA)IBA 06/2014 - 09/2010
2	Temozolomide (Temodar)FDA LinkGeneric 06/2014 - 01/2014
2	PR-957IBA 01/2014 - 12/2013
2	carfilzomibIBA 01/2014 - 12/2013
2	Core Binding Factors (Core-Binding Factor)IBA 10/2011 - 03/2011
2	Biological ProductsIBA 03/2011 - 10/2005
2	CCAAT-Enhancer-Binding ProteinsIBA 03/2011 - 01/2005
2	fludarabineIBA 01/2006 - 12/2004
1	Ifosfamide FDA LinkGeneric 11/2022
1	AlbuminsIBA 11/2022
1	Cisplatin (Platino)FDA LinkGeneric 11/2022
1	Aurora Kinase AIBA 06/2022
1	AntigensIBA 08/2021
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 06/2021
1	Topoisomerase I InhibitorsIBA 06/2021
1	Irinotecan (Camptosar)FDA LinkGeneric 06/2021
1	ixazomibIBA 01/2021
1	ChromatinIBA 12/2020
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2020

Therapy/Procedure

33	Therapeutics 01/2022 - 10/2005
17	Drug Therapy (Chemotherapy) 01/2021 - 02/2003
14	Radiotherapy 11/2022 - 02/2003
10	Aftercare (After-Treatment) 02/2022 - 11/2010
3	Complementary Therapies (Alternative Medicine) 01/2021 - 01/2016
2	Immunotherapy 08/2021 - 01/2021
2	Stem Cell Transplantation 06/2012 - 09/2010
1	Nephrectomy 11/2022
1	Intravenous Infusions 07/2021
1	Injections 12/2020
1	Music Therapy 05/2020